Table 2.
Variable | No. of Meetings (% Sample) | No. of Question-Votes (% Sample) | No. of Questions (% Sample) |
---|---|---|---|
Year | |||
1997 | 15 (4.0%) | 481 (3.1%) | 53 (4.5%) |
1998 | 11 (2.9%) | 250 (1.6%) | 23 (2.0%) |
1999 | 14 (3.7%) | 272 (1.7%) | 35 (3.0%) |
2000 | 11 (2.9%) | 393 (2.5%) | 42 (3.6%) |
2001 | 23 (6.1%) | 996 (6.3%) | 86 (7.4%) |
2002 | 22 (5.8%) | 787 (5.0%) | 63 (5.4%) |
2003 | 33 (8.7%) | 1,467 (9.3%) | 113 (9.7%) |
2004 | 16 (4.2%) | 1,039 (6.6%) | 75 (6.4%) |
2005 | 31 (8.2%) | 1,627 (10.3%) | 108 (9.3%) |
2006 | 25 (6.6%) | 1,134 (7.2%) | 83 (7.1%) |
2007 | 26 (6.9%) | 1,013 (6.4%) | 66 (5.7%) |
2008 | 37 (9.8%) | 1,711 (10.9%) | 114 (9.8%) |
2009 | 45 (11.9%) | 1,549 (9.8%) | 111 (9.5%) |
2010 | 40 (10.6%) | 1,576 (10.0%) | 99 (8.5%) |
2011 | 30 (7.9%) | 1,444 (9.2%) | 97 (8.3%) |
Advisory Committee | |||
Anti-infective drugs | 30 (7.9%) | 1,455 (9.2%) | 100 (8.6%) |
Anesthetic and life support drugs | 10 (2.6%) | 246 (1.6%) | 18 (1.5%) |
Arthritis drugs | 22 (5.8%) | 756 (4.8%) | 47 (4.0%) |
Antiviral drugs | 20 (5.3%) | 419 (2.7%) | 30 (2.6%) |
Cardiovascular and renal drugs | 60 (15.8%) | 1,732 (11.0%) | 166 (14.2%) |
Dermatologic and renal drugs | 24 (6.3%) | 754 (4.8%) | 67 (5.7%) |
Endocrine and metabolic drugs | 37 (9.8%) | 1,740 (11.1%) | 142 (12.2%) |
Gastrointestinal drugs | 19 (5.0%) | 1,141 (7.3%) | 86 (7.4%) |
Nonprescription drugs | 13 (3.4%) | 1,090 (6.9%) | 58 (5.0%) |
Oncologic drugs | 48 (12.7%) | 1,408 (9.0%) | 106 (9.1%) |
Pulmonary-allergy drugs | 19 (5.0%) | 1,089 (6.9%) | 72 (6.2%) |
Peripheral and central nervous system drugs | 23 (6.1%) | 1,386 (8.8%) | 94 (8.1%) |
Psychopharmacologic drugs | 20 (5.3%) | 914 (5.8%) | 72 (6.2%) |
Pharmaceutical science and clinical pharmacology drugs | 20 (5.3%) | 560 (3.6%) | 50 (4.3%) |
Reproductive health drugs | 14 (3.7%) | 1,049 (6.7%) | 60 (5.1%) |
Total | 379 (100.0%) | 15,739 (100.0%) | 1,168 (100.0%) |
Percentages may not add up exactly to 100% because of rounding.